Abstract:Well-controlled type 1 diabetes mellitus (T1DM) is regarded as a model of subclinical cardiovascular disease (CVD), characterized by inflammation and adverse vascular health. However, the underlying mechanisms are not fully understood. We investigated insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) levels, their correlation to miR-106b-3p expression in a subclinical CVD model, and the cardioprotective effect of metformin. A total of 20 controls and 29 well-controlled T1DM subjects were studied. Plasma IGF-1, IGFBP-3 levels, and miR-106b-3p expression in colony-forming unit-Hills were analyzed and compared with vascular markers. miR-106b-3p was upregulated in T1DM (p < 0.05) and negatively correlated with pro-angiogenic markers CD34+/100-lymphocytes (p < 0.05) and IGF-1 (p < 0.05). IGF-1 was downregulated in T1DM (p < 0.01), which was associated with increased inflammatory markers TNF-α, CRP, and IL-10 and reduced CD34+/100-lymphocytes. IGFBP-3 had no significant results. Metformin had no effect on IGF-1 but significantly reduced miR-106b-3p (p < 0.0001). An Ingenuity Pathway analysis predicted miR-106b-3p to inhibit PDGFA, PIK3CG, GDNF, and ADAMTS13, which activated CVD. Metformin was predicted to be cardioprotective by inhibiting miR-106b-3p. In conclusion: Subclinical CVD is characterized by a cardio-adverse profile of low IGF-1 and upregulated miR-106b-3p. We demonstrated that the cardioprotective effect of metformin may be via downregulation of upregulated miR-106b-3p and its effect on downstream targets.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the negative correlation between the up - regulation of anti - angiogenic microRNA miR - 106b - 3p and insulin - like growth factor - 1 (IGF - 1) and vascular health parameters in type 1 diabetes mellitus (T1DM) as a sub - clinical cardiovascular disease (CVD) model, as well as the effect of metformin treatment on these indicators. Specifically: 1. **Research Background**: - Cardiovascular disease (CVD) is the leading cause of death worldwide, and diabetes is one of the important factors increasing the risk of CVD. - Although type 1 diabetes (T1DM) still significantly increases the risk of CVD death under well - controlled conditions, its underlying mechanisms have not been fully elucidated. 2. **Research Objectives**: - To explore the levels of IGF - 1 and IGF - binding protein - 3 (IGFBP - 3) and their correlation with miR - 106b - 3p expression. - To evaluate the expression of miR - 106b - 3p in T1DM patients and its relationship with vascular health markers. - To study the effect of metformin on the expression of IGF - 1, IGFBP - 3 and miR - 106b - 3p. 3. **Main Hypotheses**: - The levels of IGF - 1 and IGFBP - 3 are decreased in T1DM and may be increased by metformin treatment. - The expression of miR - 106b - 3p is up - regulated in T1DM, and metformin can down - regulate its expression. 4. **Research Methods**: - 29 T1DM patients and 20 age - and - sex - matched healthy control subjects were recruited. - The levels of IGF - 1 and IGFBP - 3 in serum were detected by ELISA. - The expression of miR - 106b - 3p in CFU - Hill colonies was detected by real - time quantitative PCR. - Linear regression analysis was used to evaluate the correlation between various indicators. - Ingenuity Pathway Analysis (IPA) software was used to predict the downstream targets of miR - 106b - 3p and their relationship with CVD development. 5. **Research Results**: - The IGF - 1 level in T1DM patients was significantly lower than that in the healthy control group, while there was no significant difference in the IGFBP - 3 level. - The expression of miR - 106b - 3p in T1DM patients was significantly up - regulated and negatively correlated with the IGF - 1 level. - Metformin treatment significantly decreased the expression of miR - 106b - 3p, but had no significant effect on the levels of IGF - 1 and IGFBP - 3. - IPA analysis predicted that miR - 106b - 3p inhibits the expression of PDGFA, PIK3CG, GDNF and ADAMTS13, thereby activating CVD development. - Metformin has anti - inflammatory and pro - angiogenic effects by inhibiting the expression of miR - 106b - 3p and activating the expression of PDGFA, PIK3CG, GDNF and ADAMTS13. In conclusion, this study aims to explore the role of miR - 106b - 3p in T1DM and its relationship with IGF - 1 and vascular health parameters, and to evaluate the protective effect of metformin. This helps to understand the mechanism of increased cardiovascular risk in T1DM patients and provides new ideas for future prevention and treatment.

Upregulation of Anti-Angiogenic miR-106b-3p Correlates Negatively with IGF-1 and Vascular Health Parameters in a Model of Subclinical Cardiovascular Disease: Study with Metformin Therapy

Metformin Therapy Attenuates Its Expression

Abstract P124: Human Small Artery MicroRNA Expression Profiles: Changes in Type 2 Diabetes and Associations with Endothelial Function

MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program

MicroRNA Expression Profiles in a Human Induced Pluripotent Stem Cell‐derived Model of Diabetic Cardiomyopathy

MicroRNA-423 may regulate diabetic vasculopathy

Mechanisms of action of metformin and its regulatory effect on microRNAs related to angiogenesis

Circulating Mir-143-3p Inhibition Protects Against Insulin Resistance in Metabolic Syndrome Via Targeting of the Insulin-Like Growth Factor 2 Receptor.

The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application

Association between metformin treatment and coronary artery inflammation based on pericoronary adipose tissue attenuation in type 2 diabetes mellitus patients

The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression

miRNA Regulation of the Hyperproliferative Phenotype of Vascular Smooth Muscle Cells in Diabetes

miR-335-3p improves type II diabetes mellitus by IGF-1 regulating macrophage polarization

Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Compromised diabetic heart function is not affected by miR-378a upregulation upon hyperglycemia

miR‐320b, a Future Expected New Biomarker for Type 2 Diabetes Mellitus Induces Dysglycemia by Targeting PTEN

Metformin upregulates mitophagy in patients with T2DM: A randomized placebo‐controlled study

Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?

Increased Expression of Circulating microRNA 101-3p in Type 1 Diabetes Patients: New Insights Into miRNA-Regulated Pathophysiological Pathways for Type 1 Diabetes

Restricting Colorectal Cancer Cell Metabolism with Metformin: An Integrated Transcriptomics Study